• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technologies Inc. Schedules Fiscal Third Quarter 2025 Earnings Conference Call

    5/7/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    LOS ANGELAS, May 7, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Monday, May 12, 2025, to discuss the Company's financial results for the fiscal third quarter ended March 31, 2025.

    To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call."

    • Date: Monday, May 12, 2025
    • Time: 8:00am ET
    • Dial-In Numbers: North America 888-880-3330 or International +1 646-357-8766

    This conference call will be webcast live and can be accessed by all interested parties at https://app.webinar.net/z9kqo2ro81l.

    Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

    A playback will be available until 12:00 midnight Eastern Time on Thursday, May 15, 2025. To listen, please dial 800-770-2030 (Toll Free) or 609-800-9909 (Toll). Use the passcode 9733287 to access the replay.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 200 patents received or filed globally. Ispire's tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company's cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on  Instagram, LinkedIn, Twitter and YouTube. Any information contained on, or that can be accessed through, the Company's website, any other website or any social media, is not a part of this press release.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company's ability to collect its accounts receivable in a timely manner, the Company's business strategies, the ability of the Company to market to the Ispire ONE™, Ispire ONE's success if meeting its goals, the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of their products on the markets; the Ispire ONE™ proving to be safe, and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2023 and any subsequent filings which Ispire makes with the U.S. Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the press release relate only to events or information as of the date on which the statements are made in the press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

    IR Contacts:

    For more information, kindly contact:

    Investor Relations

    Sherry Zheng

    718.213.7386

    [email protected]

    KCSA Strategic Communications

    Phil Carlson

    212.896.1233

    [email protected]

    PR Contact:

    Ellen Mellody

    570.209.2947

    [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/ispire-technologies-inc-schedules-fiscal-third-quarter-2025-earnings-conference-call-302447991.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    SEC Filings

    See more
    • Ispire Technology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/15/25 4:30:11 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/12/25 7:00:13 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Ispire Technology Inc.

      10-Q - Ispire Technology Inc. (0001948455) (Filer)

      5/9/25 4:30:50 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

      Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

      5/15/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

      Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

      5/12/25 7:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technologies Inc. Schedules Fiscal Third Quarter 2025 Earnings Conference Call

      LOS ANGELAS, May 7, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Monday, May 12, 2025, to discuss the Company's financial results for the fiscal third quarter ended March 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Monday, May 12, 2025Time: 8:00am ETDial-In Numbers: North America 888-880-3330 or International +1 646-357-8766This conference call will be webcast live and can be accessed by all

      5/7/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Ispire Technology with a new price target

      ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

      5/20/24 7:18:59 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Financials

    Live finance-specific insights

    See more
    • Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

      Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

      5/12/25 7:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technologies Inc. Schedules Fiscal Third Quarter 2025 Earnings Conference Call

      LOS ANGELAS, May 7, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Monday, May 12, 2025, to discuss the Company's financial results for the fiscal third quarter ended March 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Monday, May 12, 2025Time: 8:00am ETDial-In Numbers: North America 888-880-3330 or International +1 646-357-8766This conference call will be webcast live and can be accessed by all

      5/7/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. to Participate in Webull Corporate Webinar Series on February 18, 2025

      LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Michael Wang, Co-Chief Executive Officer, will present at the Webull Consumer Webinar Series: Consumer, on February 18, 2025. Conference Details: Webull Corporate Webinar Series - ConsumerDate/Time: Tuesday, February 18th at approximately 3:00 p.m. ETPresenter: Michael Wang, Co-CEORegistration Link: HERERecent Highlights: 2/10/25: Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025 1/22/25: Ispire Technology Inc. Announces Stock Repurchase Program 1/15/25: Ispi

      2/12/25 8:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

      Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

      5/15/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Announces Key Leadership Appointments

      LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or "the Company") (NASDAQ:ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, announced today the appointment of Michael Wang as its Co-Chief Executive Officer.  Mr. Wang previously served as Chief Financial Officer. Concurrently, Daniel J. Machock was appointed as the new Chief Financial Officer. Mr. Wang has assumed the role of Co-Chief Executive Officer alongside Tuanfang Liu, as Co-Chief Executive Officer. This strengthened leadership structure is designed to refine Ispire's strategic direction and spearhead the Company's future growth. Ispire's decision

      8/14/23 8:35:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ispire Technology Inc.

      SC 13G - Ispire Technology Inc. (0001948455) (Subject)

      7/12/24 5:00:02 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CLO and Secretary Pryzbyla Steven P. sold $1,785 worth of shares (500 units at $3.57), decreasing direct ownership by 0.12% to 416,710 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      3/19/25 4:30:15 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • CLO and Secretary Pryzbyla Steven P. sold $24,982 worth of shares (6,200 units at $4.03), decreasing direct ownership by 1% to 417,210 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      3/14/25 4:30:05 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Cox Brent was granted 8,077 shares, increasing direct ownership by 63% to 20,998 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      1/10/25 6:05:19 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care